APP and Alzheimer disease: Based on the observation that Cdk5 is hyper-activated and pioglitazone can inhibit its kinase activity in APP/PS1 mutant mice, it is of great interest to examine whether pioglitazone can rescue the synaptic defects in AD mouse brains.